Advertisement

Evidence-Based Guidance for Breast Cancer Survivorship

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer Statistics, 2022.
        CA: A Cancer J Clinicians. 2022; 72: 7-33
      1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022-2024. Atlanta: American Cancer Society; 2022.

      2. National Cancer Institute. Office of Cancer Survivorship. Accessed2022.

        • McLaughlin S.A.
        • Brunelle C.L.
        • Taghian A.
        Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.
        J Clin Oncol. 2020; 38: 2341-2350
        • McDuff S.G.R.
        • Mina A.I.
        • Brunelle C.L.
        • et al.
        Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?.
        Int J Radiat Oncol Biol Phys. 2019; 103: 62-70
        • Asdourian M.S.
        • Swaroop M.N.
        • Sayegh H.E.
        • et al.
        Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
        J Clin Oncol. 2017; 35: 3934-3941
        • Tevaarwerk A.
        • Denlinger C.S.
        • Sanft T.
        • et al.
        Survivorship, Version 1.2021.
        J Natl Compr Canc Netw. 2021; 19: 676-685
        • Denlinger C.S.
        • Sanft T.
        • Baker K.S.
        • et al.
        Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
        J Natl Compr Canc Netw. 2018; 16: 1216-1247
        • McNeely M.L.
        • Magee D.J.
        • Lees A.W.
        • et al.
        The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial.
        Breast Cancer Res Treat. 2004; 86: 95-106
        • Ezzo J.
        • Manheimer E.
        • McNeely M.L.
        • et al.
        Manual lymphatic drainage for lymphedema following breast cancer treatment.
        Cochrane Database Syst Rev. 2015; : CD003475
        • Shao Y.
        • Qi K.
        • Zhou Q.H.
        • et al.
        Intermittent pneumatic compression pump for breast cancer-related lymphedema: a systematic review and meta-analysis of randomized controlled trials.
        Oncol Res Treat. 2014; 37: 170-174
        • Schmitz K.H.
        • Ahmed R.L.
        • Troxel A.B.
        • et al.
        Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial.
        JAMA. 2010; 304: 2699-2705
        • Schmitz K.H.
        • Troxel A.B.
        • Dean L.T.
        • et al.
        Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial.
        JAMA Oncol. 2019; 5: 1605-1613
        • Bandos H.
        • Melnikow J.
        • Rivera D.R.
        • et al.
        Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
        J Natl Cancer Inst. 2018; 110
        • Smith E.M.
        • Pang H.
        • Cirrincione C.
        • et al.
        Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
        JAMA. 2013; 309: 1359-1367
        • Loprinzi C.L.
        • Lacchetti C.
        • Bleeker J.
        • et al.
        Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.
        J Clin Oncol. 2020; 38: 3325-3348
        • Childs D.S.
        • Le-Rademacher J.G.
        • McMurray R.
        • et al.
        Randomized Trial of Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy: Crossover Analysis.
        J Pain Symptom Manage. 2021; 61: 1247-1253
        • Chang H.Y.
        • Jotwani A.C.
        • Lai Y.H.
        • et al.
        Hot flashes in breast cancer survivors: Frequency, severity and impact.
        Breast. 2016; 27: 116-121
        • Huang A.J.
        • Subak L.L.
        • Wing R.
        • et al.
        An intensive behavioral weight loss intervention and hot flushes in women.
        Arch Intern Med. 2010; 170: 1161-1167
        • Daley A.
        • Stokes-Lampard H.
        • Thomas A.
        • et al.
        Exercise for vasomotor menopausal symptoms.
        Cochrane Database Syst Rev. 2014; 11: CD006108
        • Holmberg L.
        • Anderson H.
        steering H, data monitoring c. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.
        Lancet. 2004; 363: 453-455
        • Loprinzi C.L.
        • Kugler J.W.
        • Sloan J.A.
        • et al.
        Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.
        Lancet. 2000; 356: 2059-2063
        • Barton D.L.
        • LaVasseur B.I.
        • Sloan J.A.
        • et al.
        Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
        J Clin Oncol. 2010; 28: 3278-3283
        • Freeman E.W.
        • Guthrie K.A.
        • Caan B.
        • et al.
        Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
        JAMA. 2011; 305: 267-274
        • Leon-Ferre R.A.
        • Novotny P.J.
        • Wolfe E.G.
        • et al.
        Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).
        JNCI Cancer Spectr. 2020; 4: pkz088
        • Bordeleau L.
        • Pritchard K.I.
        • Loprinzi C.L.
        • et al.
        Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.
        J Clin Oncol. 2010; 28: 5147-5152
        • Ataei-Almanghadim K.
        • Farshbaf-Khalili A.
        • Ostadrahimi A.R.
        • et al.
        The effect of oral capsule of curcumin and vitamin E on the hot flashes and anxiety in postmenopausal women: A triple blind randomised controlled trial.
        Complement Ther Med. 2020; 48: 102267
        • Barton D.L.
        • Loprinzi C.L.
        • Quella S.K.
        • et al.
        Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
        J Clin Oncol. 1998; 16: 495-500
        • Lesi G.
        • Razzini G.
        • Musti M.A.
        • et al.
        Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT).
        J Clin Oncol. 2016; 34: 1795-1802
        • Othman A.H.
        • Zaky A.H.
        Management of hot flushes in breast cancer survivors: comparison between stellate ganglion block and pregabalin.
        Pain Med. 2014; 15: 410-417
        • Rahimzadeh P.
        • Imani F.
        • Nafissi N.
        • et al.
        Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors.
        Cancer Manag Res. 2018; 10: 4831-4837
        • Walega D.R.
        • Rubin L.H.
        • Banuvar S.
        • et al.
        Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women.
        Menopause. 2014; 21: 807-814
        • Elkins G.
        • Marcus J.
        • Stearns V.
        • et al.
        Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.
        J Clin Oncol. 2008; 26: 5022-5026
        • Elkins G.R.
        • Fisher W.I.
        • Johnson A.K.
        Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial.
        Menopause. 2013; 20: 291-298
        • Cook E.D.
        • Iglehart E.I.
        • Baum G.
        • et al.
        Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.
        Menopause. 2017; 24: 1360-1364
        • Cathcart-Rake E.
        • O'Connor J.
        • Ridgeway J.L.
        • et al.
        Patients' Perspectives and Advice on How to Discuss Sexual Orientation, Gender Identity, and Sexual Health in Oncology Clinics.
        Am J Hosp Palliat Care. 2020; 37: 1053-1061
        • Cathcart-Rake E.
        • O'Connor J.M.
        • Ridgeway J.L.
        • et al.
        Querying Patients With Cancer About Sexual Health and Sexual and Gender Minority Status: A Qualitative Study of Health-Care Providers.
        Am J Hosp Palliat Care. 2020; 37: 418-423
        • Santen R.
        Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
        Climacteric. 2015; 18: 121-134
        • Le Ray I.
        • Dell'Aniello S.
        • Bonnetain F.
        • et al.
        Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
        Breast Cancer Res Treat. 2012; 135: 603-609
        • Barton D.L.
        • Shuster L.T.
        • Dockter T.
        • et al.
        Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
        Support Care Cancer. 2018; 26: 1335-1343
        • Bygdeman M.
        • Swahn M.L.
        Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women.
        Maturitas. 1996; 23: 259-263
        • Mitchell C.M.
        • Reed S.D.
        • Diem S.
        • et al.
        Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial.
        JAMA Intern Med. 2018; 178: 681-690
        • Loprinzi C.L.
        • Abu-Ghazaleh S.
        • Sloan J.A.
        • et al.
        Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer.
        J Clin Oncol. 1997; 15: 969-973
        • Carter J.
        • Baser R.E.
        • Goldfrank D.J.
        • et al.
        A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
        Support Care Cancer. 2021; 29: 311-322
        • Pagano T.
        • De Rosa P.
        • Vallone R.
        • et al.
        Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study.
        Menopause. 2018; 25: 657-662
        • Quick A.M.
        • Zvinovski F.
        • Hudson C.
        • et al.
        Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors.
        Support Care Cancer. 2020; 28: 3669-3677
        • Gordon C.
        • Gonzales S.
        • Krychman M.L.
        Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy.
        Menopause. 2019; 26: 423-427
        • Li F.G.
        • Maheux-Lacroix S.
        • Deans R.
        • et al.
        Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial.
        JAMA. 2021; 326: 1381-1389
        • Sussman T.A.
        • Kruse M.L.
        • Thacker H.L.
        • et al.
        Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy.
        J Oncol Pract. 2019; 15: 363-370
        • Boykoff N.
        • Moieni M.
        • Subramanian S.K.
        Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.
        J Cancer Surviv. 2009; 3: 223-232
        • Jim H.S.
        • Phillips K.M.
        • Chait S.
        • et al.
        Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.
        J Clin Oncol. 2012; 30: 3578-3587
        • Wagner L.I.
        • Gray R.J.
        • Sparano J.A.
        • et al.
        Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
        J Clin Oncol. 2020; 38: 1875-1886
        • Deprez S.
        • Amant F.
        • Smeets A.
        • et al.
        Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.
        J Clin Oncol. 2012; 30: 274-281
        • Deprez S.
        • Vandenbulcke M.
        • Peeters R.
        • et al.
        Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints.
        J Clin Oncol. 2014; 32: 2031-2038
        • Hurria A.
        • Somlo G.
        • Ahles T.
        Renaming "chemobrain.
        Cancer Invest. 2007; 25: 373-377
        • Galantino M.L.
        • Greene L.
        • Daniels L.
        • et al.
        Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series.
        Explore (NY). 2012; 8: 127-135
        • Salerno E.A.
        • Culakova E.
        • Kleckner A.S.
        • et al.
        Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study.
        J Clin Oncol. 2021; 39: 3283-3292
        • Hartman S.J.
        • Nelson S.H.
        • Myers E.
        • et al.
        Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study.
        Cancer. 2018; 124: 192-202
        • Alvarez J.
        • Meyer F.L.
        • Granoff D.L.
        • et al.
        The effect of EEG biofeedback on reducing postcancer cognitive impairment.
        Integr Cancer Ther. 2013; 12: 475-487
        • Dos Santos M.
        • Hardy-Leger I.
        • Rigal O.
        • et al.
        Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial.
        Cancer. 2020; 126: 5328-5336
        • Von Ah D.
        • Carpenter J.S.
        • Saykin A.
        • et al.
        Advanced cognitive training for breast cancer survivors: a randomized controlled trial.
        Breast Cancer Res Treat. 2012; 135: 799-809
        • Kohli S.
        • Fisher S.G.
        • Tra Y.
        • et al.
        The effect of modafinil on cognitive function in breast cancer survivors.
        Cancer. 2009; 115: 2605-2616
        • Sood A.
        • Barton D.L.
        • Loprinzi C.L.
        Use of methylphenidate in patients with cancer.
        Am J Hosp Palliat Care. 2006; 23: 35-40
        • Crew K.D.
        • Greenlee H.
        • Capodice J.
        • et al.
        Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
        J Clin Oncol. 2007; 25: 3877-3883
        • Henry N.L.
        • Giles J.T.
        • Ang D.
        • et al.
        Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
        Breast Cancer Res Treat. 2008; 111: 365-372
        • Henry N.L.
        • Giles J.T.
        • Stearns V.
        Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
        Oncology (Williston Park). 2008; 22: 1401-1408
        • Irwin M.L.
        • Cartmel B.
        • Gross C.P.
        • et al.
        Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.
        J Clin Oncol. 2015; 33: 1104-1111
        • Hershman D.L.
        • Unger J.M.
        • Crew K.D.
        • et al.
        Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
        J Clin Oncol. 2015; 33: 1910-1917
        • Shen S.
        • Unger J.M.
        • Crew K.D.
        • et al.
        Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
        Breast Cancer Res Treat. 2018; 172: 603-610
        • Hershman D.L.
        • Unger J.M.
        • Greenlee H.
        • et al.
        Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.
        JAMA. 2018; 320: 167-176
        • Henry N.L.
        • Unger J.M.
        • Schott A.F.
        • et al.
        Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
        J Clin Oncol. 2018; 36: 326-332
        • Bower J.E.
        • Bak K.
        • Berger A.
        • et al.
        Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.
        J Clin Oncol. 2014; 32: 1840-1850
        • Berger A.M.
        • Abernethy A.P.
        • Atkinson A.
        • et al.
        NCCN Clinical Practice Guidelines Cancer-related fatigue.
        J Natl Compr Canc Netw. 2010; 8: 904-931
        • Hoffman C.J.
        • Ersser S.J.
        • Hopkinson J.B.
        • et al.
        Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial.
        J Clin Oncol. 2012; 30: 1335-1342
        • Kiecolt-Glaser J.K.
        • Bennett J.M.
        • Andridge R.
        • et al.
        Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.
        J Clin Oncol. 2014; 32: 1040-1049
        • Bower J.E.
        • Garet D.
        • Sternlieb B.
        • et al.
        Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial.
        Cancer. 2012; 118: 3766-3775
        • Zetzl T.
        • Renner A.
        • Pittig A.
        • et al.
        Yoga effectively reduces fatigue and symptoms of depression in patients with different types of cancer.
        Support Care Cancer. 2021; 29: 2973-2982
        • Barton D.L.
        • Liu H.
        • Dakhil S.R.
        • et al.
        Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.
        J Natl Cancer Inst. 2013; 105: 1230-1238
        • Posadzki P.
        • Watson L.K.
        • Ernst E.
        Adverse effects of herbal medicines: an overview of systematic reviews.
        Clin Med (Lond). 2013; 13: 7-12
        • Gallicchio L.
        • Calhoun C.
        • Helzlsouer K.J.
        Aromatase inhibitor therapy and hair loss among breast cancer survivors.
        Breast Cancer Res Treat. 2013; 142: 435-443
        • Moscetti L.
        • Agnese Fabbri M.
        • Sperduti I.
        • et al.
        Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?.
        Tumori. 2015; 101: 469-473
        • Freites-Martinez A.
        • Shapiro J.
        • Chan D.
        • et al.
        Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
        JAMA Dermatol. 2018; 154: 670-675
        • Kuo A.M.
        • Reingold R.E.
        • Ketosugbo K.
        • et al.
        Oral minoxidil fo rthe treatment of late alopecia in cancer survivors, Abstract #12022.
        Am Soc Clin Oncol Annu Meet. 2022; 2022
        • Delanian S.
        • Porcher R.
        • Rudant J.
        • et al.
        Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis.
        J Clin Oncol. 2005; 23: 8570-8579
        • Jacobson G.
        • Bhatia S.
        • Smith B.J.
        • et al.
        Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.
        Int J Radiat Oncol Biol Phys. 2013; 85: 604-608
        • Magnusson M.
        • Hoglund P.
        • Johansson K.
        • et al.
        Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5).
        Eur J Cancer. 2009; 45: 2488-2495
        • Rossi A.M.
        • Nehal K.S.
        • Lee E.H.
        Radiation-induced Breast Telangiectasias Treated with the Pulsed Dye Laser.
        J Clin Aesthet Dermatol. 2014; 7: 34-37
        • Carreira H.
        • Williams R.
        • Dempsey H.
        • et al.
        Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom.
        J Cancer Surviv. 2021; 15: 564-575
        • Carreira H.
        • Williams R.
        • Funston G.
        • et al.
        Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom.
        Plos Med. 2021; 18: e1003504
        • Smith S.L.
        • Singh-Carlson S.
        • Downie L.
        • et al.
        Survivors of breast cancer: patient perspectives on survivorship care planning.
        J Cancer Surviv. 2011; 5: 337-344
        • Ye M.
        • Du K.
        • Zhou J.
        • et al.
        A meta-analysis of the efficacy of cognitive behavior therapy on quality of life and psychological health of breast cancer survivors and patients.
        Psychooncology. 2018; 27: 1695-1703
        • Arico D.
        • Raggi A.
        • Ferri R.
        Cognitive Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Review of the Literature.
        Front Psychol. 2016; 7: 1162
        • Mustian K.M.
        Yoga as Treatment for Insomnia Among Cancer Patients and Survivors: A Systematic Review.
        Eur Med J Oncol. 2013; 1: 106-115
        • Ni X.
        • Chan R.J.
        • Yates P.
        • et al.
        The effects of Tai Chi on quality of life of cancer survivors: a systematic review and meta-analysis.
        Support Care Cancer. 2019; 27: 3701-3716
        • Stearns V.
        • Johnson M.D.
        • Rae J.M.
        • et al.
        Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
        J Natl Cancer Inst. 2003; 95: 1758-1764
        • Kelly C.M.
        • Juurlink D.N.
        • Gomes T.
        • et al.
        Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
        BMJ. 2010; 340: c693
        • Desmarais J.E.
        • Looper K.J.
        Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
        J Clin Psychiatry. 2009; 70: 1688-1697
        • Kerwin J.P.
        • Gordon P.R.
        • Senf J.H.
        The variable response of women with menopausal hot flashes when treated with sertraline.
        Menopause. 2007; 14: 841-845
        • Loprinzi C.L.
        • Sloan J.
        • Stearns V.
        • et al.
        Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.
        J Clin Oncol. 2009; 27: 2831-2837
      3. Nutrition recommendations during and after treatment.
        American Society of Clinical Oncology. 2022;
        • Rock C.L.
        • Thomson C.A.
        • Sullivan K.R.
        • et al.
        American Cancer Society nutrition and physical activity guideline for cancer survivors.
        CA Cancer J Clin. 2022; 72: 230-262
        • Lahart I.M.
        • Metsios G.S.
        • Nevill A.M.
        • et al.
        Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies.
        Acta Oncol. 2015; 54: 635-654
        • Friedenreich C.M.
        • Stone C.R.
        • Cheung W.Y.
        • et al.
        Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis.
        JNCI Cancer Spectr. 2020; 4: pkz080
        • Lee J.
        A Meta-analysis of the Association Between Physical Activity and Breast Cancer Mortality.
        Cancer Nurs. 2019; 42: 271-285
        • Friedenreich C.M.
        • Shaw E.
        • Neilson H.K.
        • et al.
        Epidemiology and biology of physical activity and cancer recurrence.
        J Mol Med (Berl). 2017; 95: 1029-1041
        • Courneya K.S.
        • Segal R.J.
        • McKenzie D.C.
        • et al.
        Effects of exercise during adjuvant chemotherapy on breast cancer outcomes.
        Med Sci Sports Exerc. 2014; 46: 1744-1751
        • Cannioto R.A.
        • Hutson A.
        • Dighe S.
        • et al.
        Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival.
        J Natl Cancer Inst. 2021; 113: 54-63
        • Toledo E.
        • Salas-Salvado J.
        • Donat-Vargas C.
        • et al.
        Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical Trial.
        JAMA Intern Med. 2015; 175: 1752-1760
        • Tantamango-Bartley Y.
        • Jaceldo-Siegl K.
        • Fan J.
        • et al.
        Vegetarian diets and the incidence of cancer in a low-risk population.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 286-294
        • Jochems S.H.J.
        • Van Osch F.H.M.
        • Bryan R.T.
        • et al.
        Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature.
        BMJ Open. 2018; 8: e014530
        • Hoy M.K.
        • Winters B.L.
        • Chlebowski R.T.
        • et al.
        Implementing a low-fat eating plan in the Women's Intervention Nutrition Study.
        J Am Diet Assoc. 2009; 109: 688-696
        • Pierce J.P.
        • Natarajan L.
        • Caan B.J.
        • et al.
        Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial.
        JAMA. 2007; 298: 289-298
        • Marinac C.R.
        • Natarajan L.
        • Sears D.D.
        • et al.
        Prolonged Nightly Fasting and Breast Cancer Risk: Findings from NHANES (2009-2010).
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 783-789
        • Marinac C.R.
        • Nelson S.H.
        • Breen C.I.
        • et al.
        Prolonged Nightly Fasting and Breast Cancer Prognosis.
        JAMA Oncol. 2016; 2: 1049-1055
        • Fraser G.E.
        • Jaceldo-Siegl K.
        • Orlich M.
        • et al.
        Dairy, soy, and risk of breast cancer: those confounded milks.
        Int J Epidemiol. 2020; 49: 1526-1537
        • Ambrosone C.B.
        • Zirpoli G.R.
        • Hutson A.D.
        • et al.
        Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
        J Clin Oncol. 2020; 38: 804-814
        • Rainey L.
        • Eriksson M.
        • Trinh T.
        • et al.
        The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk.
        Int J Cancer. 2020; 147: 931-939
        • Irwin B.
        • Kimmick G.
        • Altomare I.
        • et al.
        Patient experience and attitudes toward addressing the cost of breast cancer care.
        Oncologist. 2014; 19: 1135-1140
        • Greenup R.A.
        • Rushing C.
        • Fish L.
        • et al.
        Financial Costs and Burden Related to Decisions for Breast Cancer Surgery.
        J Oncol Pract. 2019; 15: e666-e676
        • Gharzai L.A.
        • Ryan K.A.
        • Szczygiel L.
        • et al.
        Financial Toxicity During Breast Cancer Treatment: A Qualitative Analysis to Inform Strategies for Mitigation.
        JCO Oncol Pract. 2021; 17: e1413-e1423
        • Hershman D.L.
        • Tsui J.
        • Wright J.D.
        • et al.
        Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.
        J Clin Oncol. 2015; 33: 1053-1059
        • Charlson J.A.
        • McGinley E.L.
        • Nattinger A.B.
        • et al.
        Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D.
        J Natl Compr Canc Netw. 2017; 15: 1509-1517
        • Niu X.
        • Roche L.M.
        • Pawlish K.S.
        • et al.
        Cancer survival disparities by health insurance status.
        Cancer Med. 2013; 2: 403-411
        • Runowicz C.D.
        • Leach C.R.
        • Henry N.L.
        • et al.
        American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
        J Clin Oncol. 2016; 34: 611-635
        • Sung H.
        • Freedman R.A.
        • Siegel R.L.
        • et al.
        Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status.
        Cancer. 2021; 127: 3310-3324
        • Patt D.A.
        • Duan Z.
        • Fang S.
        • et al.
        Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
        J Clin Oncol. 2007; 25: 3871-3876
        • Fisher B.
        • Costantino J.P.
        • Redmond C.K.
        • et al.
        Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
        J Natl Cancer Inst. 1994; 86: 527-537
        • Bakker M.F.
        • de Lange S.V.
        • Pijnappel R.M.
        • et al.
        Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.
        N Engl J Med. 2019; 381: 2091-2102
        • Shermis R.B.
        • Wilson K.D.
        • Doyle M.T.
        • et al.
        Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue.
        AJR Am J Roentgenol. 2016; 207: 450-457
        • Partridge A.H.
        • Niman S.M.
        • Ruggeri M.
        • et al.
        Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
        Breast. 2021; 59: 327-338
        • Anderson C.
        • Engel S.M.
        • Anders C.K.
        • et al.
        Live birth outcomes after adolescent and young adult breast cancer.
        Int J Cancer. 2018; 142: 1994-2002
        • Moorman P.G.
        • Havrilesky L.J.
        • Gierisch J.M.
        • et al.
        Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
        J Clin Oncol. 2013; 31: 4188-4198
        • Morch L.S.
        • Skovlund C.W.
        • Hannaford P.C.
        • et al.
        Contemporary Hormonal Contraception and the Risk of Breast Cancer.
        N Engl J Med. 2017; 377: 2228-2239
        • Dinger J.
        • Bardenheuer K.
        • Minh T.D.
        Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer.
        Contraception. 2011; 83: 211-217
        • Backman T.
        • Rauramo I.
        • Jaakkola K.
        • et al.
        Use of the levonorgestrel-releasing intrauterine system and breast cancer.
        Obstet Gynecol. 2005; 106: 813-817
        • Kwan M.L.
        • Yao S.
        • Laurent C.A.
        • et al.
        Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
        Breast Cancer Res Treat. 2017; 168: 523-530
        • Mehta L.S.
        • Watson K.E.
        • Barac A.
        • et al.
        Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.
        Circulation. 2018; 137: e30-e66
        • Gnant M.
        • Mlineritsch B.
        • Schippinger W.
        • et al.
        Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
        N Engl J Med. 2009; 360: 679-691
        • Early Breast Cancer Trialists' Collaborative G.
        Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
        Lancet. 2015; 386: 1353-1361
        • Coleman R.
        • Finkelstein D.M.
        • Barrios C.
        • et al.
        Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 60-72
        • Gnant M.
        • Pfeiler G.
        • Steger G.G.
        • et al.
        Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2019; 20: 339-351
        • Kizub D.A.
        • Miao J.
        • Schubert M.M.
        • et al.
        Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).
        Support Care Cancer. 2021; 29: 2509-2517
      4. Barrio AV, Montagna G, Sevilimedu V, Gomez EA, Mehrara B, Morrow M. GS4-01. Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study. Presented at San Antonion Breast Cancer Symposium. 2021.

        • Haynes-Maslow L.
        • Allicock M.
        • Johnson L.S.
        Cancer Support Needs for African American Breast Cancer Survivors and Caregivers.
        J Cancer Educ. 2016; 31: 166-171
        • Bettencourt B.A.
        • Schlegel R.J.
        • Talley A.E.
        • et al.
        The breast cancer experience of rural women: a literature review.
        Psychooncology. 2007; 16: 875-887
        • Boehmer U.
        • Ozonoff A.
        • Timm A.
        • et al.
        After breast cancer: sexual functioning of sexual minority survivors.
        J Sex Res. 2014; 51: 681-689
        • Brown M.T.
        • McElroy J.A.
        Unmet support needs of sexual and gender minority breast cancer survivors.
        Support Care Cancer. 2018; 26: 1189-1196
        • Taylor E.T.
        • Bryson M.K.
        Cancer's Margins: Trans∗ and Gender Nonconforming People's Access to Knowledge, Experiences of Cancer Health, and Decision-Making.
        LGBT Health. 2015; 3: 79-89
        • Griggs J.
        • Maingi S.
        • Blinder V.
        • et al.
        American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations.
        J Clin Oncol. 2017; 35: 2203-2208
        • Lee Smith J.
        • Hall I.J.
        Advancing Health Equity in Cancer Survivorship: Opportunities for Public Health.
        Am J Prev Med. 2015; 49: S477-S482